Certara today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2018 were supported by Certara software or services.
Certara Publishes New Report Investigating Success Factors for Outcomes-based Contracting, Giving Guidelines to Pharma and Payers
Analytica Laser and BaseCase Introduce Certara Evidence & Access Solutions for US Managed Markets PRINCETON, NJ – Dec. 19, 2018 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced a new research report that investigates the potential of pharmaceutical outcomes-based contracting. The paper, entitled “Outcomes-based Agreements […]
Certara Launches BaseCase Toolkits to Facilitate Pharmaceutical and Medical Device Field Teams’ HCP and Payer Presentations
PRINCETON, NJ – Dec. 5, 2018 – Certara today announced the launch of its BaseCase Toolkits, an add-on to BaseCase Interactive which helps pharmaceutical and medical device field representatives better manage and utilize their resources for use during customer presentations.
PRINCETON, NJ – Nov. 28, 2018 – Certara today announced the launch of version 2.3 of its Trial Simulator software to help drug developers improve clinical trial design, resulting in greater likelihood of trial success.
PRINCETON, NJ – Nov. 14, 2018 – Certara today announced that it has been awarded two new dermal virtual bioequivalence grants by the US Food and Drug Administration (FDA).
Certara’s Evidence, Value & Access Specialists to Host Symposium on Automation in Public Health Decision-making and Present 18 Posters at ISPOR Europe
PRINCETON, NJ – Nov. 8, 2018 – Certara today announced that its Evidence, Value & Access team will host an educational symposium and present 18 research posters at ISPOR Europe 2018.
PRINCETON, NJ – Nov. 1, 2018 – Certara today announced that its scientists will lead 15 sessions, and also host a Phoenix User Group Meeting, at the American Association of Pharmaceutical Scientists’ (AAPS) Annual Meeting – PharmSci 360.
Certara’s Dr. Craig Rayner Awarded 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University
PRINCETON, NJ – Oct. 24, 2018 – Certara today announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Certara’s Synchrogenix Division Collaborates with Hedera Hashgraph to Offer Data Flow and Transparent Collaboration Solutions for the Life Sciences Industry
October 15, 2018 – Certara today announced that it has formed a strategic collaboration with Hedera Hashgraph. Synchrogenix®, Certara’s regulatory sciences division, has been building distributed applications in the life sciences and healthcare markets that will expand its reach in the areas of transparency and disclosure, regulatory reporting and data sharing, and collaboration/communications from drug development through market access.
FDA Renews and Expands Its Use of Certara Software to Facilitate New Drug and Biologics Regulatory Review
PRINCETON, NJ – Oct. 9, 2018 – Certara today announced that the US Food and Drug Administration (FDA) has renewed, and in many cases increased, its number of Certara software licenses for reviewing new drug and biologics applications.